Eli Lilly—which has already staged multiple efforts in court to protect sales of its diabetes and obesity meds Mounjaro and Zepbound from compounders—is launching a new salvo focused on the potential safety risks behind a common compounding tactic. More: In
read moreAs AstraZeneca kicks off the third year of its hockey-themed “Get Body Checked Against Cancer” campaign, the pharma has tapped two celebs known for their work both on and off the ice. More: AstraZeneca recruits Joshua Jackson, Philadelphia Flyers’ Gritty
read moreEli Lilly continued staggering sales growth in the fourth quarter, nearly tripling that of any other top 25 drugmaker. Meanwhile, most companies are expecting a slowdown in growth in 2026. More: As Lilly flourishes in Q4, peer projections signal looming
read moreVeeva Systems, which offers life sciences companies cloud-based commercial management software and business consulting services, is venturing into the consumer-facing side of things with the acquisition of Ostro. More: Veeva shells out 0M for Ostro and its AI chat tool
read moreThe $3 billion investment will take shape over the next ten years, the company said, and will increase the global supply of its oral GLP-1 prospect orforglipron. More: Lilly beefs up oral GLP-1 capacity with B manufacturing pledge in China
read moreAfter strutting its stuff against blockbusters in three head-to-head psoriasis trials, UCB’s Bimzelx has conquered another powerhouse product—AbbVie’s Skyrizi—in psoriatic arthritis in a head-to-head phase 3b study. More: UCB's Bimzelx continues winning streak with victory over AbbVie's Skyrizi Source: fierce
read more© 1994 - 2026 B.M. Pharmaceuticals